Top 10 Mid Cap Stocks For 2014

Top 10 Mid Cap Stocks For 2014: ViroPharma Incorporated(VPHM)

ViroPharma Incorporated, a biotechnology company, develops and commercializes therapeutic products that address serious diseases in the United States and internationally. It focuses on developing products used by physician specialists or in hospital settings. The company markets and sells Cinryze, a C1 esterase inhibitor therapy for the routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema, a life-threatening genetic disorder; and Vancocin HCl capsule, an oral capsule formulation for the treatment of C. difficile-associated diarrhea (CDAD) and to treat enterocolitis caused by staphylococcus aureus, including methicillin-resistant strains. It also offers Plenadren, an orphan drug for treatment of adrenal insufficiency in adults; Buccolam, a oromucosal solution for treatment of prolonged, acute, and convulsive seizures in infants, toddlers, children, and adolescents; and maribavir, an antiviral compound for the treatment o f CMV disease through a license agreement with GlaxoSmithKline. The company?s primary development programs include Cinryze, a C1 esterase inhibitor for management of hereditary angioedema; and VP 20621, a non-toxigenic strain of C. difficile. Its clinical stage drug candidate comprises VP-20629 for the treatment of Friedreich?s Ataxia. The company sells its products directly to wholesale drug distributors and specialty pharmacies/distributors. ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania.

Advisors' Opinion:

• [By George Budwell]

  Shire plc (NASDAQ: SHPG  ) is in the process of buying orphan drug-specialist ViroPharma (NASDAQ: VPHM  ) for $4.2 billion, strengthening Shire's already robust commercial drug portfolio for rare diseases. The deal is expected to be finalized no later than Jan! . 9, after Shire extended its tender offer to acquire all outstanding ViroPharma shares last week.

• [By MONEYMORNING]

  On Monday, Dublin-based pharmaceutical firm Shire (Nasdaq ADR: SHPG) announced that it will buy Pennsylvania-based ViroPharma (Nasdaq: VPHM) for $4.2 billion in cash. The $50 per share purchase price is a 27% premium to Viropharma's Friday close and a 64% premium to the price when sale rumors first emerged this summer.

• [By David Williamson and Alison Southwick]

  In this segment from Monday's episode, health-care analyst David Williamson discusses Shire (NASDAQ: SHPG  ) , a biopharmaceutical company focusing on rare diseases, that just beat out several rivals with its bid of $4.2 billion to acquire ViroPharma (NASDAQ: VPHM  ) . ViroPharma sells the successful hereditary angioedema drug Cinryze, which is used in prophylactic treatment of the disease. Shire sees this as an immediately complementary fit with its drug Firazyr, which is for patients already suffering from the active disease.

source from Top Stocks Blog:http://www.topstocksblog.com/top-10-mid-cap-stocks-for-2014.html